Steriwave ICU Pilot Study
Key facts
- Who runs it
- Fraser Health
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 227 people enrolled
- Started
- 18 Mar 2025
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Antimicrobial photodynamic therapy (aPDT) nasal decolonization device
- Record updated
- 5 March 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- All ICU patients 19 years and above
- Expected length of ICU stay >48 hrs
Who cannot take part
- Allergy to methylene blue and/or chlorhexidine gluconate, or unknown allergy status
- Pregnant/breastfeeding individuals
- Nasal or facial trauma that limits access to the nose
- Inability for the patients to tolerate or comply with treatment, as determined by their treating physician
- Patient, TSDM or MRP declines participation
- Co-enrolment with other research studies will be considered in an individual basis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-center, non-blinded, prospective, pilot study enrolling patients admitted to the critical care unit at Royal Columbian Hospital. This study investigates the effects of universal nasal decolonization using antimicrobial photodynamic therapy (aPDT) on the prevention of hospital-acquired pneumonia (HAP), ventilator-acquired pneumonia (VAP), and hospital-acquired bloodstream infection (BSI) in this patient population.
Read full original descriptionShow less
Main Objectives include:
* To determine whether a large, multi-center RCT of this protocol is feasible * To determine baseline rates of VAP, HAP, and ICU-acquired BSI * To gather preliminary efficacy data regarding VAP, HAP, and ICU-acquired BSI prevention using universal aPDT nasal decolonization * To gather preliminary microbiological data on the effect of universal aPDT procedures on nasal carriage of various microoganisms in ICU patients.
The 2 groups in the trial
- Control ArmNo study treatment, for comparison
The first two months will constitute the control period before the aPDT intervention is introduced into the unit. No nasal decolonization procedures (current standard of care) will take place at this time. All patients enrolled in the study will receive a nasal swab upon ICU admission, and once every four days during their stay.
- Intervention ArmTreatment being tested
Nasal decolonization procedures will be administered every other day. Just as during the intervention period, a nasal swab will be administered every four days to assess the microbiology of the nose prior to the scheduled nasal decontamination treatment
Treatment: Antimicrobial photodynamic therapy (aPDT) nasal decolonization device
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Suppression of microbial burden to reduce pneumonia in critical illness: the SMURF feasibility pilot study.Critical care (London, England), 2026
- Record updated
- 5 March 2026